Skip to main content
background gradient

Volume 12Issue 10

Industry Update

Open Access
Access in all areas? A round up of developments in market access and health technology assessment: part 1
  • Ramiro Gilardino,
  • Catrin Treharne,
  • Silvy Mardiguian, and
  • Sreeram V Ramagopalan
e230129
Published Online:16 August 2023
Preview Abstract

White Paper

Open Access
White bagging, brown bagging and site of service policies: best practices in addressing provider markup in the commercial insurance market
  • Caroline Pearson,
  • Lindsey Schapiro, and
  • Steven D Pearson
e230128
Published Online:19 September 2023
Preview Abstract

Research Article

Open Access
Regional differences in the utilization and outcomes of cerebral embolic protection during transcatheter aortic valve replacement: an analysis of the National Inpatient Sample from 2017 through 2019
  • Elisa M Amoroso
e230010
Published Online:19 September 2023
Preview Abstract
Open Access
Real-world impact of patient-reported outcome measurement on overall survival, healthcare use and treatment discontinuation in cancer patients
  • Jessie T Yan,
  • Devon J Boyne,
  • Ernest Lo,
  • Eliya Farah,
  • Dylan E O'Sullivan, and
  • Winson Y Cheung
e230061
Published Online:9 August 2023
Preview Abstract
Open Access
Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care
  • Neil Hawkins,
  • Noemi Muszbek,
  • Rachel Evans,
  • Linda McNamara, and
  • Trefor Jones
e230017
Published Online:29 August 2023
Preview Abstract
Open Access
The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA
  • Jesse Fishman,
  • Koo Wilson,
  • Aleksandra Drzewiecka,
  • Michał Pochopień, and
  • David Dingli
e230055
Published Online:1 September 2023
Preview Abstract
Open Access
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada
  • Hamza Alshannaq,
  • John J Isitt,
  • Richard F Pollock,
  • Gregory J Norman,
  • Greg Cogswell,
  • Peter M Lynch, and
  • Stéphane Roze
e230075
Published Online:5 September 2023
Preview Abstract

Review

Open Access
Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations
  • Andreas Freitag,
  • Laura Gurskyte, and
  • Grammati Sarri
e230046
Published Online:21 August 2023
Preview Abstract